Shionogi's Oral COVID Drug Set For Global Access Through MPP
Hot On Heels Of PIII Data
Agreement with UN-affiliated body set to expand global availability in lower income countries of Japanese firm’s protease inhibitor, which has faced approval road bumps at home but now looks set to move forward on positive new Phase III data.
